A ll-trans retinoic acid (ATRA), a natural retinoid derived from vitamin A, has recently been reported to induce differentiation and inhibit proliferation, cell migration, inflammation, and extracellular matrix synthesis of vascular smooth muscle cells (VSMCs). [1] [2] [3] [4] Moreover, ATRA is reported to suppress neointima formation and restenosis after balloon injury in vivo. 5, 6 In vascular endothelium, ATRA as well as other retinoids is reported to modulate endothelial cell growth and phenotype 7, 8 ; to induce antithrombotic genes including urokinase-type plasminogen activator, 9 tissue-type plasminogen activator, 10 and thrombomodulin 11 ; and to improve acetylcholine (ACh)-induced relaxation in rat aorta. 12 ATRA is thus considered to have favorable effects not only in VSMCs but also in vascular endothelium. However, roles of ATRA in endothelium still remain unclear.
Nitric oxide (NO) is a potent vasodilator and signal modulator molecule, and endothelium-derived NO in particular plays important roles in controlling vascular function, including suppression of vascular remodeling. 13, 14 With regard to the effects of ATRA on NO synthesis in endothelium, although a previous study has demonstrated its increase by ATRA through alteration of the metabolism of endogenous NO synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA), 15 little is known about the effects of ATRA on endothelium-derived NO production with regard to endothelial NOS (eNOS) function. We therefore examined the effects of ATRA on NO production as well as eNOS phosphorylation regulation in vascular endothelial cells (ECs).
Methods

Reagents
ATRA, wortmannin, LY294002, N -nitro-L-arginine methyl ester (L-NAME), and ACh were purchased from Sigma-Aldrich. The synthetic retinoic acid receptor (RAR) agonist Am580, RAR antagonist LE540, and retinoid X receptor (RXR) antagonist HX603 were synthesized as previously described. 16 -18 Diaminofluorescein-2 diacetate (DAF-2DA) was purchased from Daiichi Pure Chemicals. Carboxy-PTIO was purchased from Dojindo.
Cell Culture
Vascular ECs were cultured on a monolayer plastic dish in a humidified incubator at 37°C with 5% CO 2 . Human dermal microvascular ECs (HMVECs) were purchased from Kurabo and cultured in HuMedia-EB2 (Kurabo) supplemented with 5% fetal bovine serum (FBS), 10 ng/mL human epidermal growth factor (hEGF), 5 ng/mL human basic fibroblast growth factor, 1 g/mL hydrocortisone, 10 g/mL heparin, 39.3 g/mL dibutyryl-cAMP, 50 g/mL gentamicin, and 50 ng/mL amphotericin-B. HMVECs were used between passages 5 and 6. Human umbilical vein ECs (HUVECs) were purchased from Clonetics and were cultured in endothelial cell basal medium (Clonetics) supplemented with 2% FBS, 10 ng/mL hEGF, 1 g/mL hydrocortisone, 12 g/mL bovine brain extract, 50 g/mL gentamicin, and 50 ng/mL amphotericin-B. HUVECs were used between passages 1 and 4. SV40-transformed rat lung vascular endothelial cell line (TRLEC-03) 19 was cultured in RPMI-1640 supplemented with 5% FBS, 100 g/mL streptomycin, and 100 g/mL penicillin.
Measurement of NO Production in ECs
NO production in cultured ECs was studied with the use of DAF-2DA as a fluorescent indicator for intracellular NO. When ECs cultured on a microcoverglass (Matsunami Glass) in 100-mm culture dish were grown to 50% confluence, they were replaced with media containing 1% resin and charcoal-treated FBS (stripped FBS). 20 ATRA and/or other retinoid was then added to the media, and cells were incubated for indicated times. ECs adherent to the microcoverglass were fixed to a homeothermal chamber, and perfusions were thereafter performed at 37°C with physiological salt solution (PSS) (in mmol/L: 145 NaCl, 4.7 KCl, 2 CaCl 2 , 1.17 MgSO 4 , 1.2 NaH 2 PO 4 , 2 pyruvate, 0.02 EDTA, 3 MOPS, 5 glucose, pH 7.40). Cells were loaded with 15 mol/L DAF-2DA for 30 minutes and were then washed with PSS for 15 minutes. DAF-2DA permeates cell membrane and converts to DAF-2, 21 which reacts with NO and changes to a triazole form (DAF-2T) that yields high fluorescence. 22 NO production was determined by measurement of DAF-2T fluorescent intensity as follows. Microscopes and fluorescent imaging systems used were previously described. 23, 24 Briefly, fluorescent NO images were obtained from microscope (model ECLIPSE E600, Nikon) equipped with ϫ20 (for HMVECs) or ϫ60 (for TRLEC-03) objective. Excitation light was passed though a 495-nm filter, and emitted light was passed through a 510-nm filter. Fluorescent images of NO were enhanced with an image intensifier (C3100, Hamamatsu Photonics) and recorded by a high-speed video system (MHS-200, Nac), and fluorescent intensity analysis was performed on a Macintosh computer with the use of the public domain NIH Image program (developed at US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). In some experiments, ACh (10 mol/L) was added to PSS for 10 minutes after the washout. ACh responsiveness was determined by increment of DAF-2T fluorescence per minute after ACh stimulation for 10 minutes (dFl/dt).
RNA Preparation/Reverse TranscriptionPolymerase Chain Reaction
Total RNAs of HUVECs and TRLEC-03 were extracted with the use of RNeasy mini kit (Qiagen) according to the manufacturer's instructions. The extracted RNAs (0.5 g) were then subjected to reverse transcription (RT)-polymerase chain reaction (PCR) by RNA PCR Kit (AMV) version 3.0 (Takara Bio) with the use of specific primers for either M3 muscarinic ACh receptor or glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). RT-PCR for human M3 receptor (forward primer: 5Ј-AAG-TCA-GAT-CAC-TAA-GCG-GA-3Ј [from position 1416 to 1435 in human M3 receptor cDNA {GenBank accession number AF498917}]; reverse primer: 5Ј-GCC-AGT-AGC-CCA-GAT-TCC-AA-3Ј [from position 1575 to 1594 in the cDNA]) (PCR product: 179 bp) was performed under the following conditions: 50°C, 30 minutes and 99°C, 5 minutes for RT with the use of oligo(dT)-adaptor primer; 94°C, 2 minutes for 1 cycle; 94°C, 1 minute; 46°C, 1 minute; 72°C, 1 minute for 37 cycles. RT-PCR for human GAPDH (forward primer: 5Ј-CCA-TGG-AGA-AGG-CTG-GGG-3Ј; reverse primer: 5Ј-CAA-AGT-TGT-CAT-GGA-TGA-CC-3Ј) 25 25 (PCR product: 308 bp) was performed under the following conditions: 37°C, 10 minutes; 42°C, 30 minutes; and 99°C, 5 minutes for RT with the use of random 9-mer; 94°C, 2 minutes for 1 cycle; 94°C, 1 minute; 56°C, 1 minute; 72°C, 1 minute for 40 cycles. The RT-PCR products were thereafter subjected to electrophoresis on 1.5% agarose gel.
Real-Time PCR
TRLEC-03 grown to 80% confluence was incubated either with or without ATRA (1 mol/L) for 48 hours, and total RNAs were harvested as described above. For determination of mRNA stability, TRLEC-03 incubated either with or without ATRA for 48 hours was coincubated with 5 g/mL actinomycin D (Nacalai Tesque) for an additional 3 or 6 hours before harvesting. Real-time PCR analyses of rat phosphoinositide 3-kinase (PI3K) catalytic subunit p110␤ and rat GAPDH were then performed with the use of the obtained total RNAs by SYBR RT-PCR Kit (Perfect Real Time) (Takara Bio) according to the manufacturer's instructions. Briefly, RT reaction (42°C, 15 minutes and 95°C, 2 minutes) was performed with 600 ng total RNAs by random 6-mer. Thereafter, obtained templates (40 ng) were used for real-time PCR reactions (95°C, 10 seconds for 1 cycle; 95°C, 5 seconds; and 60°C, 20 seconds for 45 cycles) with the use of SYBR Green I by Smart Cycler (Cephied). Standard curves were obtained by real-time PCR with the use of serial dilutions of templates (40 ng, 10 ng, 4 ng, 1 ng, 400 pg, and 100 pg), and threshold cycle values were calculated.
The following primer sequences were used: rat PI3K catalytic subunit p110␤ 
Protein Preparation/Western Blotting
HMVECs were cultured in a 6-well dish, and TRLEC-03 was cultured in a 100-mm dish. When cells were grown to 80% confluence, they were replaced with media containing 1% stripped FBS. 20 Cells were then incubated with or without ATRA and/or other retinoid for indicated times. Total cellular extracts were prepared as follows. Cells were washed with cold phosphate buffered saline (PBS) 3 times, then 100 L (for HMVECs) or 300 L (for TRLEC-03) of cell lysis buffer (in mmol/L: 100 NaCl, 20 Tris-HCl, pH 7.40, 2.5 EDTA, 10 NaF, 1 Na 3 VO 4 , 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail [Complete Mini, Rosh]) was added. The mixtures were homogenized with Polytron homogenizer for 30 seconds, and cell debris was removed by centrifugation at 14 000g for 10 minutes. For Western blotting of eNOS and Akt of HMVECs and Akt and PI3K catalytic subunit p110␤ of TRLEC-03, their crude proteins (30 g for HMVECs and 100 g for TRLEC-03) were added to 2ϫ SDS sample buffer (125 mmol/L Tris-HCl, pH 6.80, 4% SDS, 20% glycerol, 100 mmol/L dithiothreitol, 0.02% bromophenol blue) and boiled at 95°C for 5 minutes. For Western blotting of eNOS of TRLEC-03, its crude extracts (500 g) were added to 75% 2Ј5Ј ADP Sepharose 4B (Amersham Biosciences) and were rotated at 4°C for 3 hours. The beads were washed with cell lysis buffer 3 times, and the bound proteins were eluted in 60 L of 1ϫ SDS sample buffer (62.5 mmol/L Tris-HCl, pH 6.80, 2% SDS, 10% glycerol, 50 mmol/L dithiothreitol, 0.01% bromophenol blue) at 95°C for 5 minutes. Nuclear extracts of TRLEC-03 for Western blotting of RAR and RXR were prepared as previously described. 26 Samples were separated on a 7.5% or a 9.0% SDS-polyacrylamide gel and were transferred onto PVDF membrane (Bio-Rad). The membranes were blocked with 5% nonfat dry milk and thereafter probed with primary antibody against either eNOS (1:1000 dilution) (Sigma); phospho-eNOS (Ser-1177) (1:400 dilution) (Cell Signaling Technology); Akt (1:1000 dilution) (Cell Signaling Technology); phospho-Akt (Ser-473) (1:500 dilution) (Cell Signaling Technology); PI3K catalytic subunit p110␤ (1:1000 dilution) (Santa Cruz); RAR␣, ␤, ␥ (all 1:400 dilution) (Santa Cruz); or RXR␣, ␤, ␥ (all 1:200 dilution). 26 In an experiment, primary antibody against inducible NOS (iNOS) (1:300 dilution) (Santa Cruz) was also used. Horseradish peroxidase-linked antibodies (Amersham Biosciences) were then used as secondary antibodies. Blotted membranes were visualized with ECL-plus reagent (Amersham Biosciences) and lumino-image analyzer LAS-1000 (Fuji Film).
Measurement of PI3K Activity
PI3K activity was measured by enzyme-linked immunosorbent assay (ELISA). When TRLEC-03 cultured in 100-mm dish was grown to 80% confluence, it was replaced with media containing 1% stripped FBS. 20 Cells were thereafter incubated with or without ATRA for indicated times. They were then washed 3 times with cold buffer A (in mmol/L: 137 NaCl, 20 Tris-HCl, pH 7.4, 1 CaCl 2 , 1 MgCl 2 , 0.1 Na 3 VO 4 ) and were lysed with 1 mL lysis buffer (buffer A with 1% NP-40 and 1 mmol/L phenylmethylsulfonyl fluoride). Cell debris was removed by centrifugation at 14 000g for 10 minutes. Five microliters of anti-PI3K regulatory subunit p85 antibody (Upstate) was added to the lysates, and they were rotated at 4°C for 1 hour. Sixty microliters of 50% protein A Sepharose (Amersham Biosciences Corp) was thereafter added to the mixtures, and they were rotated at 4°C for another hour. The beads were washed 3 times with wash buffer (buffer A with 1% NP-40), then 3 times with TNE buffer (in mmol/L: 10 Tris-HCl, pH 7.4, 150 NaCl, 5 EDTA, 0.1 Na 3 VO 4 ). Immunoprecipitated proteins were incubated with PI(4,5)P 2 substrates in vitro, and PI(3,4,5)P 3 products were measured with the use of PI3-kinase ELISA kit (Echelon Biosciences) according to the manufacturer's instructions.
Transient Transfection Studies
Human full-length wild-type eNOS cDNA (3.6 kb) was isolated by RT-PCR from HMVEC total RNAs with the use of specific primers (forward: 5Ј-CCCAAGCTTACCATGGGCAACTTGAAGAG-CCTG-3Ј; reverse: 5Ј-GGAATTCAGGGGCTGTTGGTGTCTGA-3Ј). The isolated cDNA was confirmed to be identical to the previously reported clone (NM_000603) by sequencing and was subcloned into pcDNA3.1 expression vector (Invitrogen) (pcDNA3/ wt-eNOS). The wild-type eNOS cDNA was then subjected to PCR-based site-directed mutagenesis to substitute Ser-1177 to Ala (pcDNA3/mut-eNOS). COS-1 cells grown on a microcoverglass (Matsunami Glass) in a 100-mm culture dish were transfected with 4 g of human RAR␣ cDNA expression vector (pSG5hRAR␣) and 16 g of pcDNA3/wt-eNOS or pcDNA3/mut-eNOS with the use of Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After transfection, cells were incubated with or without ATRA (1 mol/L) for 48 hours. Cells were then subjected to measurement of NO production with the use of DAF-2DA as described above in vascular ECs.
In some experiments, TRLEC-03 grown in a 100-mm dish was transfected with 10 g of pcDNA3/wt-eNOS and 10 g of wild-type Akt cDNA expression vector [Akt1 (wt) in pUSEamp(ϩ), Upstate] or dominant-negative Akt cDNA expression vector [Akt1 (K179M) in pUSEamp(ϩ), Upstate] with the use of Lipofectamine 2000 (Invitrogen). Cells were then incubated with or without ATRA (1 mol/L) for 48 hours. Their total cellular extracts were then prepared and were subjected to Western blotting as described above.
Statistical Analyses
All data are presented as meanϮSEM. Statistical analyses were performed with ANOVA followed by post hoc Tukey test.
Results
Effects of ATRA on NO Production in Vascular ECs
Effects of ATRA on NO production were first examined. 
Effects of NO Scavenger and NOS Inhibitor on NO Increase
To confirm whether the DAF-2T fluorescence increase was specifically derived from NO increase, effects of specific NO scavenger carboxy-PTIO 28 
Involvement of Retinoid Receptors in NO Increase
We examined involvement of retinoid receptors in the ATRAinduced NO increase. Western blotting revealed that TRLEC-03 expressed RAR␣, RAR␤ ( Figure 4A 
Effects of PI3K Inhibitor on NO Increase
Because several reports demonstrated involvement of PI3K in NO increase after various stimuli, including vascular endo- thelial growth factor 29 and estradiol, 30 we next examined the effects of the PI3K inhibitor wortmannin and LY294002 ( Figure 4D 
Effects of ATRA on eNOS Phosphorylation at Ser-1177
To examine involvement of eNOS in the NO increase, Western blotting with the use of antibody against phosphoeNOS (Ser-1177) or eNOS was performed. ATRA significantly increased eNOS phosphorylation at Ser-1177 in HMVECs ( Figure 5A Figure 5C ) revealed that ATRA increased eNOS phosphorylation after 48 hours (lane 3). ATRA did not increase iNOS protein expression (data not shown). These data suggest that ATRA enhances eNOS phosphorylation at Ser-1177, mediated through RAR and PI3K, later than 48 hours.
Effects of ATRA on Akt Phosphorylation
Akt, a serine/threonine protein kinase that lies downstream of PI3K and is a major target of PI3K, is known to directly phosphorylate eNOS at Ser-1177, which results in enhancement of eNOS activity and increase of NO production from vascular ECs. 31, 32 We therefore examined involvement of Akt in the ATRA-induced eNOS phosphorylation ( Figure 5D 3 and 7) . Moreover, ATRA increased Akt phosphorylation in a concentration-dependent manner ( Figure 6C ). These data suggest that ATRA phosphorylates Akt at Ser-473, mediated through RAR and PI3K, later than 48 hours.
Effects of ATRA on PI3K Activity/Catalytic Subunit p110␤ Protein Expression
Effects of ATRA on PI3K activity in TRLEC-03 were next examined. PI3K activity assay revealed that ATRA markedly increased PI3K activity after 48 hours ( Figure 7A , 460Ϯ28% of 0 hour) but not by 24 hours. Because ATRA is known to induce expression of PI3K catalytic subunit p110␤ protein and increase PI3K activity in a neuroblastoma cell line, 33 we next examined effects of ATRA on p110␤ protein expression in TRLEC-03. ATRA significantly increased p110␤ protein Time course analyses ( Figure 7C ) revealed that ATRA increased p110␤ protein expression after 48 hours. Moreover, ATRA increased p110␤ protein expression around 10 Ϫ7 and 10 Ϫ6 mol/L ( Figure 7D) , consistent with the ATRA-induced NO increase. These data suggest that ATRA increases PI3K catalytic subunit p110␤ protein expression and PI3K activity, mediated through RAR, later than 48 hours.
Effects of ATRA on PI3K Catalytic Subunit p110␤ mRNA Expression
Effects of ATRA on PI3K catalytic subunit p110␤ mRNA expression in TRLEC-03 were next examined by real-time PCR with the use of SYBR Green I. As shown in standard curves of Figure 7E , the threshold cycle values for the mRNA of p110␤ and GAPDH showed good correlation with the amount of templates in the real-time PCR analyses, indicating the reliability of the obtained data. As shown in Figure 7F , ATRA treatment (1 mol/L, 48 hours) significantly increased p110␤ mRNA expression [205Ϯ21% of ATRA(Ϫ)]. To examine ATRA effects on p110␤ mRNA stability, we next treated the cells with actinomycin D for an additional 3 or 6 hours. As shown in Figure 7G , p110␤ mRNA equally degraded either in the absence or presence of ATRA. These data indicate that ATRA induces increase of PI3K catalytic subunit p110␤ mRNA expression without affecting its stability.
Involvement of eNOS Ser-1177 in NO Increase
To examine direct involvement of eNOS Ser-1177 in the ATRA-induced NO increase, we next transfected either wild-type eNOS or mutated eNOS with RAR␣ into COS-1 cells and incubated the cells with or without ATRA (1 mol/L) for 48 hours. As shown in Figure 8 , ATRA induced NO increase (lane 2, 205Ϯ14% of lane 1) in the presence of wild-type eNOS. In contrast, ATRA could not induce NO production in the presence of mutated eNOS whose Ser-1177 was substituted to Ala (lanes 3 and 4). These data indicate direct involvement of eNOS Ser-1177, most likely by its phosphorylation, in the ATRA-induced NO increase.
Discussion
In the present study we demonstrated increase of NO production by ATRA mediated by eNOS phosphorylation through activation of the PI3K/Akt pathway in vascular ECs. We first demonstrated ATRA-induced increase of NO production. The fluorescent NO indicator DAF-2 DA was used to determine NO production, and its specificity was confirmed by inhibition of its fluorescence by treatment with either the NOS inhibitor L-NAME or the specific NO scavenger carboxy-PTIO. ATRA increased NO production in a concentrationdependent manner from 10 Ϫ7 to 10 Ϫ6 mol/L. The physiological concentration of basal plasma ATRA is Ϸ10 Ϫ8 mol/L, and the pharmacological concentration of plasma ATRA after oral administration in patients with leukemia or solid tumor reaches Ͻ10 Ϫ6 mol/L. 34 Therefore, ATRA can induce NO increase not only at pharmacological concentrations but also at physiological concentrations. In addition to the increase of basal NO production, ATRA was also demonstrated to enhance ACh-induced NO release. Because expression of M3 muscarinic ACh receptor, which is known to mediate ACh action predominantly in the vasculature, 27 has been demonstrated in both HUVECs and TRLEC-03, the observed ACh-induced NO release may be mediated through the M3 receptor. Our data are consistent with the previous report describing improvement of ACh-induced relaxation response of blood vessel by ATRA treatment. 12 Because attenuation of ACh-induced relaxation response is usually observed under endothelial dysfunction, the ATRA effect may be beneficial for recovery of responsiveness to ACh in cases of endothelial damage.
We also demonstrated that the ATRA-induced NO increase was mediated by eNOS phosphorylation at Ser-1177 through the PI3K/Akt pathway, as previously observed in vascular endothelial growth factor 29 and estradiol. 30 Because a previous study has demonstrated NO increase by ATRA through alteration of the metabolism of the endogenous NOS inhibitor ADMA, 15 ATRA may affect NO production through a dual mechanism. The PI3K/Akt pathway is reported to play important roles in vascular ECs, including cell survival 35 and migration. 36 ATRA may therefore be able to affect endothelial function other than eNOS activation through the PI3K/ Akt pathway. Time course analyses demonstrated that NO increase as well as eNOS phosphorylation was observed later than 48 hours after ATRA treatment. Consistent with their time course, Akt phosphorylation, PI3K activity increase, and PI3K catalytic subunit p110␤ protein expression were also observed later than 48 hours after ATRA treatment. of PI3K catalytic subunit p110␤ protein expression in TRLEC-03. Cells were incubated with ATRA for 48 hours at indicated concentrations. In B to D, Western blotting with the use of antibody against PI3K catalytic subunit p110␤ protein (p110␤) was performed. E, Standard curves for real-time PCR analyses of PI3K catalytic subunit p110␤ (PI3K p110␤) and GAPDH mRNAs. Serial dilutions of templates (40 ng, 10 ng, 4 ng, 1 ng, 400 pg, and 100 pg) were used for real-time PCR, and obtained threshold cycle (Ct) values of each mRNA were plotted against amounts of templates. The equations of the lines for each mRNA were calculated by linear regression analyses. PI3K p110␤: yϭϪ1.2214ϫ50.43; GAPDH: yϭϪ0.9817ϫ31.829. F, Effects of ATRA on PI3K catalytic subunit p110␤ mRNA expression in TRLEC-03 examined by real-time PCR. Cells were incubated for 48 hours either with [ATRA(ϩ)] or without [ATRA(Ϫ)] 1 mol/L ATRA. Bar graphs represent meanϮSEM (nϭ6) of p110␤ mRNA levels normalized by GAPDH mRNA levels. *PϽ0.05 vs ATRA(Ϫ). G, Effect of ATRA on PI3K catalytic subunit p110␤ mRNA stability examined by real-time PCR. TRLEC-03 incubated either with or without 1 mol/L ATRA for 48 hours was further incubated with actinomycin D (5 g/mL) for an additional 3 or 6 hours. Lines represent meanϮSEM (nϭ4) of p110␤ mRNA levels normalized by GAPDH mRNA levels.
We showed the expression of both retinoid receptors, RAR and RXR, in vascular ECs. ATRA binds to and activates RAR. However, ATRA easily converts to 9-cis retinoic acid, which binds to and activates both RAR and RXR, by intracellular reciprocal isomerization. 37 Therefore, administration of ATRA would activate both retinoid receptors. We thus used receptor-selective antagonists to define the retinoid receptors involved in the ATRA-induced NO increase. The RAR antagonist LE540, but not the RXR antagonist HX603, suppressed ATRA-induced NO increase. Because HX603 concentration (1 mol/L) is enough for inhibiting RXR agonist-mediated RXR transactivation, 18 we speculate that RXR may not be involved in the NO increase. Furthermore, ATRA-induced eNOS phosphorylation, Akt phosphorylation, and PI3K catalytic subunit p110␤ protein increase were all inhibited by LE540. Moreover, the RAR agonist Am580 was shown to induce NO increase, eNOS phosphorylation, and Akt phosphorylation. This therefore indicates that ATRA-activated RAR induces PI3K catalytic subunit p110␤ protein expression to increase PI3K activity, resulting in sequential phosphorylation of Akt and eNOS. Real-time PCR analyses demonstrated a significant increase of PI3K catalytic subunit p110␤ mRNA expression by ATRA, indicating that the ATRA-induced p110␤ protein increase was most likely due to its mRNA increase. The ATRA-induced increase of p110␤ mRNA expression may possibly be due to RAR-mediated increase of gene transcription, because p110␤ mRNA stability was not affected by ATRA. Further studies are needed to examine ATRA/RAR effects on PI3K catalytic subunit p110␤ gene transcription by analyzing its promoter activity.
Antiproliferative effects of retinoids, including ATRA, have recently been reported in VSMCs. 2 ATRA inhibits VSMC proliferation by modulation of cell cycle regulators, 38 downregulation of angiotensin II type 1 receptor expression, 4, 39 and induction of apoptosis. 40 Moreover, ATRA suppresses neointima formation and restenosis after balloon injury in vivo. 5, 6 In contrast to VSMCs, effects of retinoids on vascular ECs have been less investigated. Our study has therefore provided a novel action of retinoids on vascular ECs in terms of improvement of endothelial function through NO production. Retinoids are thus beneficial for both VSMCs and vascular ECs against cardiovascular disorders. Recently, new synthetic retinoids with fewer side effects such as Am80 were improved and obtained good results in the hematology field. 41 Therefore, improvement of novel retinoids may provide novel therapeutic treatments not only in proliferative vascular diseases but also in vascular diseases with endothelial damage.
In conclusion, we have shown that ATRA increases NO production by eNOS phosphorylation through RAR-mediated activation of the PI3K/Akt pathway in vascular ECs and possibly plays a beneficial role in the vascular endothelium. Retinoids may therefore be candidates for novel therapeutic agents against vascular disorders with endothelial damage.
